Clinical Trial Update: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating molecular features in postmenopausal women with HR+/HER2-negative advanced breast cancer treated first-line with ribociclib plus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• Faslodex (fulvestrant)
• KISQALI (ribociclib)
• Piqray (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED